$ATNM

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals (NYSE American: ATNM) said it will present new ATNM-400 (Actinium-225 antibody radioconjugate) data at SNMMI 2026 in Los Angeles May 30–June 2, with three posters on prostate cancer, NSCLC, and radioconjugate optimization. Separately, NYSE American notified the company it is not in compliance with $4.0m stockholders’ equity requirements; Actinium must submit a compliance plan by June 26, 2026.

Original reporting
Published May 29, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice — source image
Decision brief

The 30-second read

$ATNMNeutralMed
01

Why it matters

The release combines (1) scheduled scientific updates at SNMMI with (2) a procedural exchange-risk timeline that can drive risk premia and liquidity concerns even without immediate delisting action.

02

Market read

Traders may weigh a near-term risk premium from potential delisting proceedings against incremental event-driven interest ahead of SNMMI data.

03

What to watch

Market reaction may hinge less on the SNMMI posters themselves and more on whether the compliance plan details are credible and whether equity financing is implied/needed.

Relevance 9/10Novelty 6/10Timing: Into SNMMI 2026 (May 30–June 2) and ahead of the June 26, 2026 compliance-plan deadline.

Background

Actinium is a targeted radiotherapies company developing Actinium-225 antibody radioconjugates (notably ATNM-400) and received an NYSE American notice for continued listing standards related to stockholders’ equity and net losses.

Company-level read

Ticker impact

$ATNMNeutralMedium confidence
Context

Actinium (ATNM) announced SNMMI 2026 ATNM-400 program updates and disclosed an NYSE American continued-listing standards non-compliance notice.

Expected impact

Near-term volatility risk from delisting headlines; incremental upside possible into SNMMI as investors price in clinical-read-through.

Evidence & confidence

The listing notice has explicit procedural timelines (plan due June 26, 2026; potential delisting by Nov 27, 2027) while the SNMMI update is promotional but time-specific for data delivery.

Market effects

Highlights ongoing capital-market/listing risk for pre-commercial biotech while reinforcing investor focus on Actinium-225 radioconjugate platform read-through.

Primarily US microcap/small-cap sentiment via NYSE American listing-risk mechanics.

Limited; conference data and exchange compliance are US-specific though radiopharma interest is global.

Counterpoint

The notice has 'no immediate effect' on trading; investors may over-discount delisting risk if the company submits an acceptable plan.

Key entities

  • Actinium Pharmaceuticals, Inc.

    Subject of the press release; provides ATNM-400 SNMMI 2026 presentation details and discloses NYSE American listing standards non-compliance notice.

  • NYSE American LLC

    Issued the continued listing standards non-compliance notice under Section 1003(a)(ii) of the Company Guide.

  • ATNM-400

    Actinium-225 antibody radioconjugate with three SNMMI 2026 presentations (prostate cancer, NSCLC, and chelator optimization).

Related articles

$ATNMMed

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

Actinium Pharmaceuticals (NYSE American: ATNM) said it expanded Actimab-A intellectual property with multiple newly issued US patents and additional pre-grant/allowed applications, covering uses in AML, MDS, and solid tumors, including combinations with venetoclax and CLAG-M. The company also amended its IND to add a manufacturing source and reported NYSE American listing compliance plan acceptance through Nov. 27, 2027.

$ATNMLow

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals said the Canadian Intellectual Property Office issued Notices of Allowance for two patent applications covering its Actimab-A and Iomab-ACT programs. The Actimab-A/CLAG-M AML combination allowance is expected to issue with a term into Jan. 2039; the CD45 conditioning for gene-edited cell therapies is expected to issue with a term into Oct. 2038. Actinium said this adds to a global portfolio of about 250 issued and pending patents.

$ALOYMed

Why REalloys Stock Soared Today

REalloys (ALOY) jumped 13.7% after reporting Q2 2026 results post-close, its second quarterly report as a public company. Revenue rose 83% to $0.8 million, helped by PMT Critical Metals sales from its Ohio facility. Net loss widened to $36.8 million, driven by $32.1 million stock-based compensation. The company says it is fully funding a facility upgrade and plans trials before year-end, with commercial intake planned for Q3 2027.

$ORCLMed

Why Oracle Stock Got Trounced Today

Oracle (ORCL) shares fell nearly 4% after a six-month delay to a natural gas pipeline project supplying power to its New Mexico AI data center complex, Project Jupiter. Transwestern Pipeline, a unit of Energy Transfer, revised the Green Chile Project in-service date to Feb. 1, 2027 from Aug. 15, according to a regulatory filing.